Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COCP NASDAQ:IMMP NASDAQ:KALA NASDAQ:SCLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOCPCocrystal Pharma$1.02-0.1%$1.19$0.86▼$2.67$14.05M1.421.29 million shs34,556 shsIMMPPrima BioMed$0.41+5.8%$0.45$0.29▼$3.53$60.87M2.217.84 million shs367,993 shsKALAKALA BIO$2.08-17.5%$3.89$2.02▼$1,030.00$38.67M-2.4121,749 shs139,877 shsSCLXScilex$7.65+7.5%$7.27$4.20▼$34.27$64.91M1.771,347 shs37,268 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOCPCocrystal Pharma0.00%+2.01%-9.38%+1.50%-31.88%IMMPPrima BioMed0.00%+5.29%-10.23%+12.57%-75.98%KALAKALA BIO0.00%-30.19%+13.00%-70.53%-98.91%SCLXScilex0.00%-4.82%-20.11%+12.32%+17.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOCPCocrystal Pharma$1.02-0.1%$1.19$0.86▼$2.67$14.05M1.421.29 million shs34,556 shsIMMPPrima BioMed$0.41+5.8%$0.45$0.29▼$3.53$60.87M2.217.84 million shs367,993 shsKALAKALA BIO$2.08-17.5%$3.89$2.02▼$1,030.00$38.67M-2.4121,749 shs139,877 shsSCLXScilex$7.65+7.5%$7.27$4.20▼$34.27$64.91M1.771,347 shs37,268 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOCPCocrystal Pharma0.00%+2.01%-9.38%+1.50%-31.88%IMMPPrima BioMed0.00%+5.29%-10.23%+12.57%-75.98%KALAKALA BIO0.00%-30.19%+13.00%-70.53%-98.91%SCLXScilex0.00%-4.82%-20.11%+12.32%+17.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOCPCocrystal Pharma 1.00SellN/AN/AIMMPPrima BioMed 2.00Hold$5.501,231.72% UpsideKALAKALA BIO 2.00Hold$1,018.7548,878.37% UpsideSCLXScilex 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest COCP, SCLX, IMMP, and KALA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026KALAKALA BIO Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/17/2026IMMPPrima BioMed Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy6/16/2026SCLXScilex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/8/2026COCPCocrystal Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026COCPCocrystal Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOCPCocrystal PharmaN/AN/AN/AN/A$0.46 per shareN/AIMMPPrima BioMed$4.08M14.92N/AN/A$0.63 per share0.66KALAKALA BION/AN/AN/AN/A$12.56 per shareN/ASCLXScilex$30.25M2.15N/AN/A($24.94) per share-0.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOCPCocrystal Pharma-$8.83M-$0.73N/AN/AN/AN/A-150.61%-97.86%8/13/2026 (Estimated)IMMPPrima BioMed-$39.78MN/AN/AN/AN/AN/AN/AN/A9/2/2026 (Estimated)KALAKALA BIO-$26.98M-$96.14N/AN/AN/AN/A-1,336.10%-94.85%8/6/2026 (Estimated)SCLXScilex-$358.73M-$40.47N/AN/AN/A-1,110.17%N/A-143.55%9/2/2026 (Estimated)Latest COCP, SCLX, IMMP, and KALA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026SCLXScilex-$0.3373-$4.76-$4.4227-$6.28$15.00 million$8.61 million5/15/2026Q1 2026COCPCocrystal Pharma-$0.15-$0.17-$0.02-$0.17$0.23 million$0.23 million5/15/2026Q1 2026KALAKALA BIO-$8.50-$0.14+$8.36-$0.14N/AN/A4/15/2026Q4 2025KALAKALA BIO-$8.50$0.86+$9.36$43.00N/AN/A4/10/2026Q4 2025SCLXScilex-$0.47-$4.60-$4.13-$4.60$12.10 million$4.79 million3/31/2026Q4 2025COCPCocrystal Pharma-$0.18-$0.17+$0.01-$0.17N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCOCPCocrystal PharmaN/AN/AN/AN/AN/AIMMPPrima BioMedN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/ASCLXScilexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOCPCocrystal PharmaN/A2.662.66IMMPPrima BioMedN/A2.97N/AKALAKALA BION/A7.917.91SCLXScilexN/A0.080.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOCPCocrystal Pharma6.72%IMMPPrima BioMed2.32%KALAKALA BIO24.61%SCLXScilex69.67%Insider OwnershipCompanyInsider OwnershipCOCPCocrystal Pharma39.40%IMMPPrima BioMed3.07%KALAKALA BIO2.24%SCLXScilex4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOCPCocrystal Pharma1013.79 million8.36 millionNot OptionableIMMPPrima BioMed2,021147.37 million142.85 millionOptionableKALAKALA BIO3018.59 million18.17 millionNot OptionableSCLXScilex808.49 million8.11 millionNo DataCOCP, SCLX, IMMP, and KALA HeadlinesRecent News About These CompaniesScilex Stockholders Approve Director Election and Equity PlanJune 24, 2026 | tipranks.comScilex (NASDAQ:SCLX) Shares Up 18% - Here's What HappenedJune 18, 2026 | americanbankingnews.comScilex Holding Company to List Dream Bowl Tokens on Biconomy Exchange Starting June 23, 2026June 16, 2026 | quiverquant.comQScilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026June 16, 2026 | globenewswire.comScilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders ...June 12, 2026 | finance.yahoo.comScilex Holding Company Announces Dividend Payment Date for Semnur Pharmaceuticals Common StockJune 12, 2026 | quiverquant.comQScilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity SecuritiesJune 12, 2026 | globenewswire.comScilex Holding Company (“Scilex”) Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of ...June 5, 2026 | theglobeandmail.comScilex Holding Company ("Scilex") Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of ...June 4, 2026 | markets.businessinsider.comScilex Holding Company (“Scilex”) Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity SecuritiesJune 4, 2026 | globenewswire.comScilex Holding Company ("Scilex") Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other ...May 22, 2026 | markets.businessinsider.comScilex Holding Company Declares Dividend of Semnur Pharmaceuticals Common Stock to ShareholdersMay 22, 2026 | quiverquant.comQScilex Holding Company (“Scilex”) Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026May 22, 2026 | globenewswire.comScilex Delays Quarterly Report Amid Consolidation WorkMay 15, 2026 | tipranks.comScilex Announces Special Dream Bowl Token DividendMay 11, 2026 | tipranks.comPHOE stock more than doubles on strategic pivot into pharma industry with Scilex dealMay 5, 2026 | msn.comScilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings LimitedMay 5, 2026 | theglobeandmail.comScilex Subsidiary Reshapes Phoenix Asia via $1B Share DealMay 5, 2026 | tipranks.comScilex Holding Company Announces Acquisition Agreement Between ACEA Therapeutics and Phoenix Asia HoldingsMay 5, 2026 | quiverquant.comQScilex Holding Company Announces Its Board of Directors Approved May 26, 2026 as the Payment Date of the Previously Announced Dividend of Dream Bowl Meme Coin I Tokens to ...May 4, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCOCP, SCLX, IMMP, and KALA Company DescriptionsCocrystal Pharma NASDAQ:COCP$1.02 0.00 (-0.10%) As of 03:24 PM Eastern This is a fair market value price provided by Massive. Learn more.Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Prima BioMed NASDAQ:IMMP$0.41 +0.02 (+5.76%) As of 03:25 PM Eastern This is a fair market value price provided by Massive. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.KALA BIO NASDAQ:KALA$2.08 -0.44 (-17.46%) As of 03:23 PM Eastern This is a fair market value price provided by Massive. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Scilex NASDAQ:SCLX$7.64 +0.54 (+7.52%) As of 03:24 PM Eastern This is a fair market value price provided by Massive. Learn more.Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right 5 Places Investors Can Hide If the AI Trade Keeps Cracking MarketBeat Week in Review – 06/22 - 06/26 Qualcomm’s Investor Day Just Changed the Growth Story Forever Is Apple’s Latest Plunge the Canary in the Coal Mine for Tech Stocks? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
